Dr Lutz Jermutus

Biog:
Lutz Jermutus is a Product Development Team Leader and Senior Director, R&D, in MedImmune’s Cardiovascular & Metabolic Diseases iMED, responsible for leading clinical candidates from late stage pre-clinical through IND to clinical proof-of-concept. He was previously the global head of technology overseeing teams in the UK and US. In this role, he was leading non-antibody biologics technologies and resulting drug projects across all disease areas. Key activities included therapeutic peptides and proteins but also novel biologics modalities such as multiselective antibodies, polyclonal antibodies, antibody-drug-conjugates, scaffolds and oligonucleotides. His team established a phenotypic selection and screening platform that delivered novel therapeutic targets across all disease areas and managed multiple technology collaborations with biotechs including Evotec, Direvo Biotech, PeptiDream, Molecular Partners, Silence Therapeutics, Xenome and Retrogenix. Previously at Cambridge Antibody Technology, Lutz was director of discovery, oncology, and director of protein engineering.